Drug Profile


Alternative Names: Epsi gam; Fc fusion protein - Tunitas Therapeutics; GE2

Latest Information Update: 27 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tunitas Therapeutics
  • Class Allergy immunotherapies; Antiallergics; Immunoglobulins; Recombinant fusion proteins
  • Mechanism of Action Fc gamma receptor IIB antagonists; IgE receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypersensitivity
  • Preclinical Asthma; Food hypersensitivity

Most Recent Events

  • 15 Jun 2016 Tunitas Therapeutics terminates a phase I trial in Hypersensitivity in Australia (NCT02559258)
  • 17 May 2016 Preclinical study data in Allergy and Asthma released by Tunitas Therapeutics
  • 05 Oct 2015 Preclinical development is ongoing Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top